Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED‐HF)
Identifieur interne : 001247 ( Istex/Corpus ); précédent : 001246; suivant : 001248Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED‐HF)
Auteurs : John J. V. Mcmurray ; Inder S. Anand ; Rafael Diaz ; Aldo P. Maggioni ; Christopher O'Connor ; Marc A. Pfeffer ; Scott D. Solomon ; Michal Tendera ; Dirk J. Van Veldhuisen ; Moetaz Albizem ; Sunfa Cheng ; Debra Scarlata ; Karl Swedberg ; James B. YoungSource :
- European Journal of Heart Failure [ 1388-9842 ] ; 2013-03.
Abstract
This report describes the baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED‐HF) which is testing the hypothesis that anaemia correction with darbepoetin alfa will reduce the composite endpoint of death from any cause or hospital admission for worsening heart failure, and improve other outcomes.
Url:
DOI: 10.1093/eurjhf/hfs204
Links to Exploration step
ISTEX:E14D0FA19E3B62D44F4FD6318CE1CA2A7B8972B9Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED‐HF)</title><author><name sortKey="Mcmurray, John J V" sort="Mcmurray, John J V" uniqKey="Mcmurray J" first="John J. V." last="Mcmurray">John J. V. Mcmurray</name><affiliation><mods:affiliation>Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, G12 8TA, Glasgow, UK</mods:affiliation></affiliation></author><author><name sortKey="Anand, Inder S" sort="Anand, Inder S" uniqKey="Anand I" first="Inder S." last="Anand">Inder S. Anand</name><affiliation><mods:affiliation>University of Minnesota Medical School and VA Medical Center, MN, Minneapolis, USA</mods:affiliation></affiliation></author><author><name sortKey="Diaz, Rafael" sort="Diaz, Rafael" uniqKey="Diaz R" first="Rafael" last="Diaz">Rafael Diaz</name><affiliation><mods:affiliation>Estudios Clinicos Latinoamerica, Rosario, Argentina</mods:affiliation></affiliation></author><author><name sortKey="Maggioni, Aldo P" sort="Maggioni, Aldo P" uniqKey="Maggioni A" first="Aldo P." last="Maggioni">Aldo P. Maggioni</name><affiliation><mods:affiliation>ANMCO Research Center, Via la Marmora, Florence, Italy</mods:affiliation></affiliation></author><author><name sortKey="O Connor, Christopher" sort="O Connor, Christopher" uniqKey="O Connor C" first="Christopher" last="O'Connor">Christopher O'Connor</name><affiliation><mods:affiliation>Duke University Medical Center, NC, Durham, USA</mods:affiliation></affiliation></author><author><name sortKey="Pfeffer, Marc A" sort="Pfeffer, Marc A" uniqKey="Pfeffer M" first="Marc A." last="Pfeffer">Marc A. Pfeffer</name><affiliation><mods:affiliation>Brigham and Women's Hospital, MA, Boston, USA</mods:affiliation></affiliation></author><author><name sortKey="Solomon, Scott D" sort="Solomon, Scott D" uniqKey="Solomon S" first="Scott D." last="Solomon">Scott D. Solomon</name><affiliation><mods:affiliation>Brigham and Women's Hospital, MA, Boston, USA</mods:affiliation></affiliation></author><author><name sortKey="Tendera, Michal" sort="Tendera, Michal" uniqKey="Tendera M" first="Michal" last="Tendera">Michal Tendera</name><affiliation><mods:affiliation>Division of Cardiology, Medical University of Silesia, Katowice, Poland</mods:affiliation></affiliation></author><author><name sortKey="Van Veldhuisen, Dirk J" sort="Van Veldhuisen, Dirk J" uniqKey="Van Veldhuisen D" first="Dirk J." last="Van Veldhuisen">Dirk J. Van Veldhuisen</name><affiliation><mods:affiliation>University Medical Center Groningen, Groningen, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Albizem, Moetaz" sort="Albizem, Moetaz" uniqKey="Albizem M" first="Moetaz" last="Albizem">Moetaz Albizem</name><affiliation><mods:affiliation>Amgen Inc., CA, USA</mods:affiliation></affiliation></author><author><name sortKey="Cheng, Sunfa" sort="Cheng, Sunfa" uniqKey="Cheng S" first="Sunfa" last="Cheng">Sunfa Cheng</name><affiliation><mods:affiliation>Amgen Inc., CA, USA</mods:affiliation></affiliation></author><author><name sortKey="Scarlata, Debra" sort="Scarlata, Debra" uniqKey="Scarlata D" first="Debra" last="Scarlata">Debra Scarlata</name><affiliation><mods:affiliation>Amgen Inc., CA, USA</mods:affiliation></affiliation></author><author><name sortKey="Swedberg, Karl" sort="Swedberg, Karl" uniqKey="Swedberg K" first="Karl" last="Swedberg">Karl Swedberg</name><affiliation><mods:affiliation>Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden</mods:affiliation></affiliation></author><author><name sortKey="Young, James B" sort="Young, James B" uniqKey="Young J" first="James B." last="Young">James B. Young</name><affiliation><mods:affiliation>Department of Medicine, Endocrinology and Metabolism Institute, Cleveland Clinic, OH, Cleveland, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E14D0FA19E3B62D44F4FD6318CE1CA2A7B8972B9</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1093/eurjhf/hfs204</idno><idno type="url">https://api.istex.fr/document/E14D0FA19E3B62D44F4FD6318CE1CA2A7B8972B9/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001247</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED‐HF)</title><author><name sortKey="Mcmurray, John J V" sort="Mcmurray, John J V" uniqKey="Mcmurray J" first="John J. V." last="Mcmurray">John J. V. Mcmurray</name><affiliation><mods:affiliation>Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, G12 8TA, Glasgow, UK</mods:affiliation></affiliation></author><author><name sortKey="Anand, Inder S" sort="Anand, Inder S" uniqKey="Anand I" first="Inder S." last="Anand">Inder S. Anand</name><affiliation><mods:affiliation>University of Minnesota Medical School and VA Medical Center, MN, Minneapolis, USA</mods:affiliation></affiliation></author><author><name sortKey="Diaz, Rafael" sort="Diaz, Rafael" uniqKey="Diaz R" first="Rafael" last="Diaz">Rafael Diaz</name><affiliation><mods:affiliation>Estudios Clinicos Latinoamerica, Rosario, Argentina</mods:affiliation></affiliation></author><author><name sortKey="Maggioni, Aldo P" sort="Maggioni, Aldo P" uniqKey="Maggioni A" first="Aldo P." last="Maggioni">Aldo P. Maggioni</name><affiliation><mods:affiliation>ANMCO Research Center, Via la Marmora, Florence, Italy</mods:affiliation></affiliation></author><author><name sortKey="O Connor, Christopher" sort="O Connor, Christopher" uniqKey="O Connor C" first="Christopher" last="O'Connor">Christopher O'Connor</name><affiliation><mods:affiliation>Duke University Medical Center, NC, Durham, USA</mods:affiliation></affiliation></author><author><name sortKey="Pfeffer, Marc A" sort="Pfeffer, Marc A" uniqKey="Pfeffer M" first="Marc A." last="Pfeffer">Marc A. Pfeffer</name><affiliation><mods:affiliation>Brigham and Women's Hospital, MA, Boston, USA</mods:affiliation></affiliation></author><author><name sortKey="Solomon, Scott D" sort="Solomon, Scott D" uniqKey="Solomon S" first="Scott D." last="Solomon">Scott D. Solomon</name><affiliation><mods:affiliation>Brigham and Women's Hospital, MA, Boston, USA</mods:affiliation></affiliation></author><author><name sortKey="Tendera, Michal" sort="Tendera, Michal" uniqKey="Tendera M" first="Michal" last="Tendera">Michal Tendera</name><affiliation><mods:affiliation>Division of Cardiology, Medical University of Silesia, Katowice, Poland</mods:affiliation></affiliation></author><author><name sortKey="Van Veldhuisen, Dirk J" sort="Van Veldhuisen, Dirk J" uniqKey="Van Veldhuisen D" first="Dirk J." last="Van Veldhuisen">Dirk J. Van Veldhuisen</name><affiliation><mods:affiliation>University Medical Center Groningen, Groningen, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Albizem, Moetaz" sort="Albizem, Moetaz" uniqKey="Albizem M" first="Moetaz" last="Albizem">Moetaz Albizem</name><affiliation><mods:affiliation>Amgen Inc., CA, USA</mods:affiliation></affiliation></author><author><name sortKey="Cheng, Sunfa" sort="Cheng, Sunfa" uniqKey="Cheng S" first="Sunfa" last="Cheng">Sunfa Cheng</name><affiliation><mods:affiliation>Amgen Inc., CA, USA</mods:affiliation></affiliation></author><author><name sortKey="Scarlata, Debra" sort="Scarlata, Debra" uniqKey="Scarlata D" first="Debra" last="Scarlata">Debra Scarlata</name><affiliation><mods:affiliation>Amgen Inc., CA, USA</mods:affiliation></affiliation></author><author><name sortKey="Swedberg, Karl" sort="Swedberg, Karl" uniqKey="Swedberg K" first="Karl" last="Swedberg">Karl Swedberg</name><affiliation><mods:affiliation>Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden</mods:affiliation></affiliation></author><author><name sortKey="Young, James B" sort="Young, James B" uniqKey="Young J" first="James B." last="Young">James B. Young</name><affiliation><mods:affiliation>Department of Medicine, Endocrinology and Metabolism Institute, Cleveland Clinic, OH, Cleveland, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">European Journal of Heart Failure</title><title level="j" type="abbrev">European Journal of Heart Failure</title><idno type="ISSN">1388-9842</idno><idno type="eISSN">1879-0844</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><date type="published" when="2013-03">2013-03</date><biblScope unit="volume">15</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="334">334</biblScope><biblScope unit="page" to="341">341</biblScope></imprint><idno type="ISSN">1388-9842</idno></series><idno type="istex">E14D0FA19E3B62D44F4FD6318CE1CA2A7B8972B9</idno><idno type="DOI">10.1093/eurjhf/hfs204</idno><idno type="ArticleID">EJHFHFS204</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1388-9842</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">This report describes the baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED‐HF) which is testing the hypothesis that anaemia correction with darbepoetin alfa will reduce the composite endpoint of death from any cause or hospital admission for worsening heart failure, and improve other outcomes.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>John J.V. McMurray</name><affiliations><json:string>Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, G12 8TA, Glasgow, UK</json:string></affiliations></json:item><json:item><name>Inder S. Anand</name><affiliations><json:string>University of Minnesota Medical School and VA Medical Center, MN, Minneapolis, USA</json:string></affiliations></json:item><json:item><name>Rafael Diaz</name><affiliations><json:string>Estudios Clinicos Latinoamerica, Rosario, Argentina</json:string></affiliations></json:item><json:item><name>Aldo P. Maggioni</name><affiliations><json:string>ANMCO Research Center, Via la Marmora, Florence, Italy</json:string></affiliations></json:item><json:item><name>Christopher O'Connor</name><affiliations><json:string>Duke University Medical Center, NC, Durham, USA</json:string></affiliations></json:item><json:item><name>Marc A. Pfeffer</name><affiliations><json:string>Brigham and Women's Hospital, MA, Boston, USA</json:string></affiliations></json:item><json:item><name>Scott D. Solomon</name><affiliations><json:string>Brigham and Women's Hospital, MA, Boston, USA</json:string></affiliations></json:item><json:item><name>Michal Tendera</name><affiliations><json:string>Division of Cardiology, Medical University of Silesia, Katowice, Poland</json:string></affiliations></json:item><json:item><name>Dirk J. van Veldhuisen</name><affiliations><json:string>University Medical Center Groningen, Groningen, The Netherlands</json:string></affiliations></json:item><json:item><name>Moetaz Albizem</name><affiliations><json:string>Amgen Inc., CA, USA</json:string></affiliations></json:item><json:item><name>Sunfa Cheng</name><affiliations><json:string>Amgen Inc., CA, USA</json:string></affiliations></json:item><json:item><name>Debra Scarlata</name><affiliations><json:string>Amgen Inc., CA, USA</json:string></affiliations></json:item><json:item><name>Karl Swedberg</name><affiliations><json:string>Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden</json:string></affiliations></json:item><json:item><name>James B. Young</name><affiliations><json:string>Department of Medicine, Endocrinology and Metabolism Institute, Cleveland Clinic, OH, Cleveland, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Heart failure</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Anaemia</value></json:item></subject><articleId><json:string>EJHFHFS204</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><qualityIndicators><score>6.636</score><pdfVersion>1.5</pdfVersion><pdfPageSize>595.276 x 793.701 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>2</keywordCount><abstractCharCount>359</abstractCharCount><pdfWordCount>6053</pdfWordCount><pdfCharCount>38593</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>53</abstractWordCount></qualityIndicators><title>Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED‐HF)</title><corporate><json:item><name>on behalf of the RED‐HF Committees Investigators</name></json:item></corporate><genre><json:string>article</json:string></genre><host><volume>15</volume><publisherId><json:string>EJHF</json:string></publisherId><pages><total>8</total><last>341</last><first>334</first></pages><issn><json:string>1388-9842</json:string></issn><issue>3</issue><subject><json:item><value>Clinical Trial</value></json:item></subject><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1879-0844</json:string></eissn><title>European Journal of Heart Failure</title><doi><json:string>10.1002/(ISSN)1879-0844</json:string></doi></host><publicationDate>2013</publicationDate><copyrightDate>2013</copyrightDate><doi><json:string>10.1093/eurjhf/hfs204</json:string></doi><id>E14D0FA19E3B62D44F4FD6318CE1CA2A7B8972B9</id><score>0.23369324</score><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/E14D0FA19E3B62D44F4FD6318CE1CA2A7B8972B9/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/E14D0FA19E3B62D44F4FD6318CE1CA2A7B8972B9/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/E14D0FA19E3B62D44F4FD6318CE1CA2A7B8972B9/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED‐HF)</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><availability status="free"><p>Open Access</p></availability><date>2013-11-26</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED‐HF)</title><author><orgName>on behalf of the RED‐HF Committees Investigators</orgName></author><author xml:id="author-1"><persName><forename type="first">John J.V.</forename><surname>McMurray</surname></persName><note type="correspondence"><p>Correspondence: Corresponding author. Tel: +44 141 330 3479, Fax: +44 141 330 6955, Email:</p></note><affiliation>Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, G12 8TA, Glasgow, UK</affiliation></author><author xml:id="author-2"><persName><forename type="first">Inder S.</forename><surname>Anand</surname></persName><affiliation>University of Minnesota Medical School and VA Medical Center, MN, Minneapolis, USA</affiliation></author><author xml:id="author-3"><persName><forename type="first">Rafael</forename><surname>Diaz</surname></persName><affiliation>Estudios Clinicos Latinoamerica, Rosario, Argentina</affiliation></author><author xml:id="author-4"><persName><forename type="first">Aldo P.</forename><surname>Maggioni</surname></persName><affiliation>ANMCO Research Center, Via la Marmora, Florence, Italy</affiliation></author><author xml:id="author-5"><persName><forename type="first">Christopher</forename><surname>O'Connor</surname></persName><affiliation>Duke University Medical Center, NC, Durham, USA</affiliation></author><author xml:id="author-6"><persName><forename type="first">Marc A.</forename><surname>Pfeffer</surname></persName><affiliation>Brigham and Women's Hospital, MA, Boston, USA</affiliation></author><author xml:id="author-7"><persName><forename type="first">Scott D.</forename><surname>Solomon</surname></persName><affiliation>Brigham and Women's Hospital, MA, Boston, USA</affiliation></author><author xml:id="author-8"><persName><forename type="first">Michal</forename><surname>Tendera</surname></persName><affiliation>Division of Cardiology, Medical University of Silesia, Katowice, Poland</affiliation></author><author xml:id="author-9"><persName><forename type="first">Dirk J.</forename><surname>van Veldhuisen</surname></persName><affiliation>University Medical Center Groningen, Groningen, The Netherlands</affiliation></author><author xml:id="author-10"><persName><forename type="first">Moetaz</forename><surname>Albizem</surname></persName><affiliation>Amgen Inc., CA, USA</affiliation></author><author xml:id="author-11"><persName><forename type="first">Sunfa</forename><surname>Cheng</surname></persName><affiliation>Amgen Inc., CA, USA</affiliation></author><author xml:id="author-12"><persName><forename type="first">Debra</forename><surname>Scarlata</surname></persName><affiliation>Amgen Inc., CA, USA</affiliation></author><author xml:id="author-13"><persName><forename type="first">Karl</forename><surname>Swedberg</surname></persName><affiliation>Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden</affiliation></author><author xml:id="author-14"><persName><forename type="first">James B.</forename><surname>Young</surname></persName><affiliation>Department of Medicine, Endocrinology and Metabolism Institute, Cleveland Clinic, OH, Cleveland, USA</affiliation></author></analytic><monogr><title level="j">European Journal of Heart Failure</title><title level="j" type="abbrev">European Journal of Heart Failure</title><idno type="pISSN">1388-9842</idno><idno type="eISSN">1879-0844</idno><idno type="DOI">10.1002/(ISSN)1879-0844</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><date type="published" when="2013-03"></date><biblScope unit="volume">15</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="334">334</biblScope><biblScope unit="page" to="341">341</biblScope></imprint></monogr><idno type="istex">E14D0FA19E3B62D44F4FD6318CE1CA2A7B8972B9</idno><idno type="DOI">10.1093/eurjhf/hfs204</idno><idno type="ArticleID">EJHFHFS204</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2013-11-26</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>This report describes the baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED‐HF) which is testing the hypothesis that anaemia correction with darbepoetin alfa will reduce the composite endpoint of death from any cause or hospital admission for worsening heart failure, and improve other outcomes.</p></abstract><abstract><p>Key demographic, clinical, and laboratory findings, along with baseline treatment, are reported and compared with those of patients in other recent clinical trials in heart failure. Compared with other recent trials, RED‐HF enrolled more elderly [mean age 70 (SD 11.4) years], female (41%), and black (9%) patients. RED‐HF patients more often had diabetes (46%) and renal impairment (72% had an estimated glomerular filtration rate <60 mL/min/1.73 m2). Patients in RED‐HF had heart failure of longer duration [5.3 (5.4) years], worse NYHA class (35% II, 63% III, and 2% IV), and more signs of congestion. Mean EF was 30% (6.8%). RED‐HF patients were well treated at randomization, and pharmacological therapy at baseline was broadly similar to that of other recent trials, taking account of study‐specific inclusion/exclusion criteria. Median (interquartile range) haemoglobin at baseline was 112 (106–117) g/L.</p></abstract><abstract><p>The anaemic patients enrolled in RED‐HF were older, moderately to markedly symptomatic, and had extensive co‐morbidity.</p></abstract><textClass><keywords scheme="keyword"><list><head>keywords</head><item><term>Heart failure</term></item><item><term>Anaemia</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article-category</head><item><term>Clinical Trial</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2012-11-06">Received</change><change when="2012-11-07">Registration</change><change when="2013-11-26">Created</change><change when="2013-03">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/E14D0FA19E3B62D44F4FD6318CE1CA2A7B8972B9/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en" xml:id="EJHFHFS204"><header><publicationMeta level="product"><doi origin="wiley">10.1002/(ISSN)1879-0844</doi><issn type="print">1388-9842</issn><issn type="electronic">1879-0844</issn><idGroup><id type="product" value="EJHF"></id></idGroup><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="5"></count><count type="referenceTotal" number="46"></count></countGroup><titleGroup><title type="main" sort="EUROPEAN JOURNAL OF HEART FAILURE">European Journal of Heart Failure</title><title type="short">European Journal of Heart Failure</title></titleGroup><attributeValueGroup><attributeValue element="legalStatement" attribute="type" value="creativeCommonsBy-nc"></attributeValue></attributeValueGroup></publicationMeta><publicationMeta level="part" position="30"><doi origin="wiley">10.1002/ejhf.2013.15.issue-3</doi><copyright ownership="publisher">© 2013 European Society of Cardiology</copyright><numberingGroup><numbering type="journalVolume" number="15">15</numbering><numbering type="journalIssue">3</numbering></numberingGroup><coverDate startDate="2013-03">March 2013</coverDate></publicationMeta><publicationMeta level="unit" position="140" type="article" status="forIssue" accessType="open"><doi origin="wiley">10.1093/eurjhf/hfs204</doi><idGroup><id type="unit" value="EJHFHFS204"></id></idGroup><countGroup><count type="pageTotal" number="8"></count></countGroup><titleGroup><title type="articleCategory">Clinical Trial</title><title type="tocHeading1">Clinical Trials</title></titleGroup><copyright ownership="thirdParty">Published on behalf of the European Society of Cardiology. All rights reserved. © 2013 the Authors</copyright><legalStatement type="creativeCommonsBy-nc"><p>This is an open access article under the terms of the <url href="http://creativecommons.org/licenses/by-nc/3.0/">Creative Commons Attribution‐NonCommercial</url> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</p></legalStatement><eventGroup><event type="manuscriptReceived" date="2012-11-06"></event><event type="manuscriptAccepted" date="2012-11-07"></event><event type="xmlCreated" agent="Aptara" date="2013-11-26"></event><event type="publishedOnlineFinalForm" date="2014-01-27"></event><event type="firstOnline" date="2014-01-27"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.6.4 mode:FullText" date="2015-10-02"></event></eventGroup><numberingGroup><numbering type="pageFirst">334</numbering><numbering type="pageLast">341</numbering></numberingGroup><correspondenceTo>Corresponding author. Tel: +44 141 330 3479, Fax: +44 141 330 6955, Email: <email>john.mcmurray@glasgow.ac.uk</email></correspondenceTo><objectNameGroup><objectName elementName="appendix">Appendix: RED‐HF trial investigators</objectName></objectNameGroup><linkGroup><link type="toTypesetVersion" href="file://EJHF.EJHFHFS204.pdf"></link></linkGroup></publicationMeta><contentMeta><titleGroup><title type="main">Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED‐HF)</title></titleGroup><creators><creator xml:id="ejhfhfs204-cr-0001" creatorRole="author" affiliationRef="#ejhfhfs204-aff-0001" corresponding="yes"><personName><familyName>McMurray</familyName><givenNames>John J.V.</givenNames></personName></creator><creator xml:id="ejhfhfs204-cr-0002" creatorRole="author" affiliationRef="#ejhfhfs204-aff-0002" corresponding="no"><personName><familyName>Anand</familyName><givenNames>Inder S.</givenNames></personName></creator><creator xml:id="ejhfhfs204-cr-0003" creatorRole="author" affiliationRef="#ejhfhfs204-aff-0003" corresponding="no"><personName><familyName>Diaz</familyName><givenNames>Rafael</givenNames></personName></creator><creator xml:id="ejhfhfs204-cr-0004" creatorRole="author" affiliationRef="#ejhfhfs204-aff-0004" corresponding="no"><personName><familyName>Maggioni</familyName><givenNames>Aldo P.</givenNames></personName></creator><creator xml:id="ejhfhfs204-cr-0005" creatorRole="author" affiliationRef="#ejhfhfs204-aff-0005" corresponding="no"><personName><familyName>O'Connor</familyName><givenNames>Christopher</givenNames></personName></creator><creator xml:id="ejhfhfs204-cr-0006" creatorRole="author" affiliationRef="#ejhfhfs204-aff-0006" corresponding="no"><personName><familyName>Pfeffer</familyName><givenNames>Marc A.</givenNames></personName></creator><creator xml:id="ejhfhfs204-cr-0007" creatorRole="author" affiliationRef="#ejhfhfs204-aff-0006" corresponding="no"><personName><familyName>Solomon</familyName><givenNames>Scott D.</givenNames></personName></creator><creator xml:id="ejhfhfs204-cr-0008" creatorRole="author" affiliationRef="#ejhfhfs204-aff-0007" corresponding="no"><personName><familyName>Tendera</familyName><givenNames>Michal</givenNames></personName></creator><creator xml:id="ejhfhfs204-cr-0009" creatorRole="author" affiliationRef="#ejhfhfs204-aff-0008" corresponding="no"><personName><familyNamePrefix>van</familyNamePrefix><familyName>Veldhuisen</familyName><givenNames>Dirk J.</givenNames></personName></creator><creator xml:id="ejhfhfs204-cr-0010" creatorRole="author" affiliationRef="#ejhfhfs204-aff-0009" corresponding="no"><personName><familyName>Albizem</familyName><givenNames>Moetaz</givenNames></personName></creator><creator xml:id="ejhfhfs204-cr-0011" creatorRole="author" affiliationRef="#ejhfhfs204-aff-0009" corresponding="no"><personName><familyName>Cheng</familyName><givenNames>Sunfa</givenNames></personName></creator><creator xml:id="ejhfhfs204-cr-0012" creatorRole="author" affiliationRef="#ejhfhfs204-aff-0009" corresponding="no"><personName><familyName>Scarlata</familyName><givenNames>Debra</givenNames></personName></creator><creator xml:id="ejhfhfs204-cr-0013" creatorRole="author" affiliationRef="#ejhfhfs204-aff-0010" corresponding="no"><personName><familyName>Swedberg</familyName><givenNames>Karl</givenNames></personName></creator><creator xml:id="ejhfhfs204-cr-0014" creatorRole="author" affiliationRef="#ejhfhfs204-aff-0011" corresponding="no"><personName><familyName>Young</familyName><givenNames>James B.</givenNames></personName></creator><creator xml:id="ejhfhfs204-cr-0015" creatorRole="author" corresponding="no"><groupName>on behalf of the RED‐HF Committees Investigators</groupName></creator></creators><affiliationGroup><affiliation xml:id="ejhfhfs204-aff-0001" type="organization" countryCode="GB"><orgDiv>Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre</orgDiv><orgName>University of Glasgow</orgName><address><postCode>G12 8TA</postCode><city>Glasgow</city><country>UK</country></address></affiliation><affiliation xml:id="ejhfhfs204-aff-0002" type="organization" countryCode="US"><orgName>University of Minnesota Medical School and VA Medical Center</orgName><address><city>Minneapolis</city><countryPart>MN</countryPart><country>USA</country></address></affiliation><affiliation xml:id="ejhfhfs204-aff-0003" type="organization" countryCode="AR"><orgName>Estudios Clinicos Latinoamerica</orgName><address><city>Rosario</city><country>Argentina</country></address></affiliation><affiliation xml:id="ejhfhfs204-aff-0004" type="organization" countryCode="IT"><orgDiv>ANMCO Research Center</orgDiv><orgName>Via la Marmora</orgName><address><city>Florence</city><country>Italy</country></address></affiliation><affiliation xml:id="ejhfhfs204-aff-0005" type="organization" countryCode="US"><orgName>Duke University Medical Center</orgName><address><city>Durham</city><countryPart>NC</countryPart><country>USA</country></address></affiliation><affiliation xml:id="ejhfhfs204-aff-0006" type="organization" countryCode="US"><orgName>Brigham and Women's Hospital</orgName><address><city>Boston</city><countryPart>MA</countryPart><country>USA</country></address></affiliation><affiliation xml:id="ejhfhfs204-aff-0007" type="organization" countryCode="PL"><orgDiv>Division of Cardiology</orgDiv><orgName>Medical University of Silesia</orgName><address><city>Katowice</city><country>Poland</country></address></affiliation><affiliation xml:id="ejhfhfs204-aff-0008" type="organization" countryCode="NL"><orgName>University Medical Center Groningen</orgName><address><city>Groningen</city><country>The Netherlands</country></address></affiliation><affiliation xml:id="ejhfhfs204-aff-0009" type="organization" countryCode="US"><orgName>Amgen Inc.</orgName><address><countryPart>CA</countryPart><country>USA</country></address></affiliation><affiliation xml:id="ejhfhfs204-aff-0010" type="organization" countryCode="SE"><orgDiv>Department of Molecular and Clinical Medicine, Sahlgrenska Academy</orgDiv><orgName>University of Gothenburg</orgName><address><city>Gothenburg</city><country>Sweden</country></address></affiliation><affiliation xml:id="ejhfhfs204-aff-0011" type="organization" countryCode="US"><orgDiv>Department of Medicine, Endocrinology and Metabolism Institute</orgDiv><orgName>Cleveland Clinic</orgName><address><city>Cleveland</city><countryPart>OH</countryPart><country>USA</country></address></affiliation></affiliationGroup><keywordGroup type="author"><keyword xml:id="ejhfhfs204-kwd-0001">Heart failure</keyword><keyword xml:id="ejhfhfs204-kwd-0002">Anaemia</keyword></keywordGroup><abstractGroup><abstract xml:id="ejhfhfs204-abs-0001" type="main"><section xml:id="ejhfhfs204-sec-0001"><title type="main">Aims</title><p>This report describes the baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED‐HF) which is testing the hypothesis that anaemia correction with darbepoetin alfa will reduce the composite endpoint of death from any cause or hospital admission for worsening heart failure, and improve other outcomes.</p></section><section xml:id="ejhfhfs204-sec-0002"><title type="main">Methods and results</title><p>Key demographic, clinical, and laboratory findings, along with baseline treatment, are reported and compared with those of patients in other recent clinical trials in heart failure. Compared with other recent trials, RED‐HF enrolled more elderly [mean age 70 (SD 11.4) years], female (41%), and black (9%) patients. RED‐HF patients more often had diabetes (46%) and renal impairment (72% had an estimated glomerular filtration rate <60 mL/min/1.73 m<sup>2</sup>). Patients in RED‐HF had heart failure of longer duration [5.3 (5.4) years], worse NYHA class (35% II, 63% III, and 2% IV), and more signs of congestion. Mean EF was 30% (6.8%). RED‐HF patients were well treated at randomization, and pharmacological therapy at baseline was broadly similar to that of other recent trials, taking account of study‐specific inclusion/exclusion criteria. Median (interquartile range) haemoglobin at baseline was 112 (106–117) g/L.</p></section><section xml:id="ejhfhfs204-sec-0003"><title type="main">Conclusion</title><p>The anaemic patients enrolled in RED‐HF were older, moderately to markedly symptomatic, and had extensive co‐morbidity.</p></section></abstract></abstractGroup></contentMeta><noteGroup xml:id="ejhfhfs204-ntgp-0001"><note xml:id="ejhfhfs204-tbl-note-0001a">This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<url href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by‐nc/3.0/</url>), which permits non‐commercial use, distribution, and reproduction in any medium, provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re‐use, please contact <email>journals.permissions@oup.com</email>.</note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED‐HF)</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED‐HF)</title></titleInfo><name type="personal"><namePart type="given">John J.V.</namePart><namePart type="family">McMurray</namePart><affiliation>Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, G12 8TA, Glasgow, UK</affiliation><description>Correspondence: Corresponding author. Tel: +44 141 330 3479, Fax: +44 141 330 6955, Email: </description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Inder S.</namePart><namePart type="family">Anand</namePart><affiliation>University of Minnesota Medical School and VA Medical Center, MN, Minneapolis, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Rafael</namePart><namePart type="family">Diaz</namePart><affiliation>Estudios Clinicos Latinoamerica, Rosario, Argentina</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Aldo P.</namePart><namePart type="family">Maggioni</namePart><affiliation>ANMCO Research Center, Via la Marmora, Florence, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christopher</namePart><namePart type="family">O'Connor</namePart><affiliation>Duke University Medical Center, NC, Durham, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Marc A.</namePart><namePart type="family">Pfeffer</namePart><affiliation>Brigham and Women's Hospital, MA, Boston, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Scott D.</namePart><namePart type="family">Solomon</namePart><affiliation>Brigham and Women's Hospital, MA, Boston, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Michal</namePart><namePart type="family">Tendera</namePart><affiliation>Division of Cardiology, Medical University of Silesia, Katowice, Poland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Dirk J.</namePart><namePart type="family">van Veldhuisen</namePart><affiliation>University Medical Center Groningen, Groningen, The Netherlands</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Moetaz</namePart><namePart type="family">Albizem</namePart><affiliation>Amgen Inc., CA, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Sunfa</namePart><namePart type="family">Cheng</namePart><affiliation>Amgen Inc., CA, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Debra</namePart><namePart type="family">Scarlata</namePart><affiliation>Amgen Inc., CA, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Karl</namePart><namePart type="family">Swedberg</namePart><affiliation>Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">James B.</namePart><namePart type="family">Young</namePart><affiliation>Department of Medicine, Endocrinology and Metabolism Institute, Cleveland Clinic, OH, Cleveland, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="corporate"><namePart>on behalf of the RED‐HF Committees Investigators</namePart></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><dateIssued encoding="w3cdtf">2013-03</dateIssued><dateCreated encoding="w3cdtf">2013-11-26</dateCreated><dateCaptured encoding="w3cdtf">2012-11-06</dateCaptured><dateValid encoding="w3cdtf">2012-11-07</dateValid><copyrightDate encoding="w3cdtf">2013</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract>This report describes the baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED‐HF) which is testing the hypothesis that anaemia correction with darbepoetin alfa will reduce the composite endpoint of death from any cause or hospital admission for worsening heart failure, and improve other outcomes.</abstract><abstract>Key demographic, clinical, and laboratory findings, along with baseline treatment, are reported and compared with those of patients in other recent clinical trials in heart failure. Compared with other recent trials, RED‐HF enrolled more elderly [mean age 70 (SD 11.4) years], female (41%), and black (9%) patients. RED‐HF patients more often had diabetes (46%) and renal impairment (72% had an estimated glomerular filtration rate <60 mL/min/1.73 m2). Patients in RED‐HF had heart failure of longer duration [5.3 (5.4) years], worse NYHA class (35% II, 63% III, and 2% IV), and more signs of congestion. Mean EF was 30% (6.8%). RED‐HF patients were well treated at randomization, and pharmacological therapy at baseline was broadly similar to that of other recent trials, taking account of study‐specific inclusion/exclusion criteria. Median (interquartile range) haemoglobin at baseline was 112 (106–117) g/L.</abstract><abstract>The anaemic patients enrolled in RED‐HF were older, moderately to markedly symptomatic, and had extensive co‐morbidity.</abstract><subject><genre>keywords</genre><topic>Heart failure</topic><topic>Anaemia</topic></subject><relatedItem type="host"><titleInfo><title>European Journal of Heart Failure</title></titleInfo><titleInfo type="abbreviated"><title>European Journal of Heart Failure</title></titleInfo><genre type="journal">journal</genre><subject><genre>article-category</genre><topic>Clinical Trial</topic></subject><identifier type="ISSN">1388-9842</identifier><identifier type="eISSN">1879-0844</identifier><identifier type="DOI">10.1002/(ISSN)1879-0844</identifier><identifier type="PublisherID">EJHF</identifier><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>334</start><end>341</end><total>8</total></extent></part></relatedItem><identifier type="istex">E14D0FA19E3B62D44F4FD6318CE1CA2A7B8972B9</identifier><identifier type="DOI">10.1093/eurjhf/hfs204</identifier><identifier type="ArticleID">EJHFHFS204</identifier><accessCondition type="use and reproduction" contentType="creativeCommonsBy-nc">This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><enrichments><json:item><type>multicat</type><uri>https://api.istex.fr/document/E14D0FA19E3B62D44F4FD6318CE1CA2A7B8972B9/enrichments/multicat</uri></json:item></enrichments><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Belgique/explor/OpenAccessBelV2/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001247 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001247 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Belgique
|area= OpenAccessBelV2
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:E14D0FA19E3B62D44F4FD6318CE1CA2A7B8972B9
|texte= Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED‐HF)
}}
| This area was generated with Dilib version V0.6.25. |  |